FR-900520 and FR-900523, novel neutral macrolide immunosuppressants, were isolated from the cultured broth of Streptomyces hygroscopicus subsp. yakushimaensis No. 7238. Their molecular formulae were determined as C43H69NO12 and C42H67NOi2, respectively.
The detection of immunosuppressants which have the ability to prevent rejection of transplanted organs has been of major interest in our laboratories. A mixed lymphocyte reaction (MLR)has been thought to be the in vitro correlative model for allograft rejection and a representative reaction of interleukin-2 (IL-2) dependent T cell proliferation. Onthe basis of this, we have searched for efficient immunosuppressantswith specific suppression of MLRin cultured broths of microorganisms isolated from soil samples.
Previously we reported the discovery of FK-506i:) which has been proven to be potentially more potent as an antirejection drug2~7) than cyclosporine (CsA)8~12), the most widely used immunosuppressant at this time.
We isolated new compounds FR-900520 and and FR-900523. The determination of their chemical structures will be reported in a later paper.
Materials and Methods

Fermentation
A loopful of the slant culture of the produc- ing strain No. 7238 was inoculated into a 500-ml Erlenmeyer flask containing 160 ml of a sterile seed mediumand incubated at 30°C for 4 days on a rotary shaker. The seed medium (adjusted to pH 6.5) was composed of glycerol (1 %), corn starch (1 %), glucose (0.5%), cotton seed meal (1 %), dried yeast (0.5%), corn steep liquor (0.5%) and calcium carbonate (0.2%). 3.2 liters of the seed culture were transferred to 150 liters of a production medium (adjusted to pH 6.8) containing glucose (4.5 %), corn steep liquor (1 %), dried yeast (1 %), gluten meal (1 %), wheat germ (0.5%), calcium carbonate (0.1 %) and Adekanol (defoaming agent, Asahi Denka Co., Ltd.) (0.1 %) in a 200-liter jar fermentor. Fermentation was carried out at 30°C for 4 days under aeration of 150 liters/minute and agitation at 250rpm.
Suppression of In Vitro MLR
The MLRtests were performed in microtiter plates, with each well containing 5 x lO5 C57BL/6 (female, 6~7 weeks old) responder cells (H-2b), 5 x lO5 mitomycin C treated (25^g/ml mitomycin C at 37°C for 30 minutes and washed three times RPMI1640 medium) BALB/C(female, 6-7 weeks old) stimulator cells (H-2d) in 0.2 ml RPMI 1640 medium supplemented with 10% fetal calf serum, 2 him sodium bicarbonate, benzylpenicillin (50 u/ml) and streptomycin (50^g/ml). The cells were incubated at 37°C in a humidified atmosphere of 5% CO2: 95% air for 68 hours and pulsed with [3H]- Antimicrobial Activities Antimicrobial activities were determined by a conventional agar dilution method, using a nutrient agar for antibacterial tests and a Sabouraud's agar for antifungal tests.
Skin Grafting Full-thickness ear skin grafts from donor rats, F344 (RT-llvl male, 8-10 weeks old) were transplanted on to the lateral thorax of recipient rats, WKA(RT-lk male, 8-10 weeks old) and covered with sterile bactericidal gauze. The entire chest was then wrapped with an elastic bandage. The dressings were removed on day 5. The grafts were inspected daily until rejection which was defined as more than 90%necrosis of the graft epithelium. FR-900520 was dissolved in olive oil and administered intramuscularly 5 days a week, for 2 weeks, beginning on the day of transplantation.
Results
Fermentation
A typical time course for the fermentation is presented in Fig. 2 . The activities in the fermenta- This oily residue was mixed with twice its weight of acidic silica gel (special silica gel grade 12, maker Fuji Devison Co., Ltd.), and this dry mixture was applied to a column of the same acidic silica gel (1,000 ml) packed with /z-hexane. The column was developed with w-hexane (3 liters), a mixture of «-hexane and ethyl acetate (4 : 1, 3 liters) and ethyl acetate (3 liters). The fractions containing the object compounds («-hexane and «-hexane -ethyl acetate, 4 : 1) were collected and concentrated in vacuo.
The oily residue was dissolved in a mixture of nhexane and ethyl acetate (1 : 1, 50ml) and subjected to column chromatography of silica gel (70-230 mesh, Merck Co., Ltd.) (1,000 ml) containing the same two solvents. The column was washed with the solvents (3 liters), and then eluted with a mixture of w-hexane and ethyl acetate (1 : 2, 3 liters) and ethyl acetate (3 liters).
The concentration of active fractions gave a crude yellowish powder (4.5 g) in which FR-900520 and FR-900523 were contained in the ratio of four to one. The powder was dissolved in methanol (20 ml) and mixed with water (10 ml). This mixture was chromatographed on YMC gel (ODS, 60~200 mesh made by Yamamura Chemical Institute) (500 ml) packed and developed with 80% aqueous methanol. Fractions were monitored by HPLCanalysis (Fig. 4) . FR-900523 and FR-900520 were eluted at elution volumes from 950 ml to 1,350 ml (Fraction I) and 1,670 ml to 2,750 ml (Fraction II), respectively.
Fraction II was concentrated in vacuo to remove methanol. After extraction with ethyl acetate, the product was completely dried and the resulting pale yellowish powder (1.8 g) was dissolved in a small amount of diethyl ether. After standing overnight, plates were obtained.
Recrystallization from the same solvent gave 600 mg of purified FR-900520 in the form of colorless plates. The ethyl acetate extract of Fraction I was concentrated in vacuo to give a pale yellowish powder (510 mg). This crude FR-900523 contaminated with FR-900520 was dissolved in acetonitrile (3 ml) and applied to YMCgel (70 ml), which was packed and developed with a mixture of acetonitrile, tetrahydrofuran and 50 mMphosphate buffer (pH 2.0) (3 : 2 : 5). Active fractions were extracted with ethyl acetate and evaporated in vacuo to dryness (190 mg). The rechromatography on YMCgel gave FR-900523 (80 mg) seperated from FR-900520. This white product, dissolved in a small amount of diethyl ether, was kept at room temperature overnight, whereupon needles (56 mg) were obtained.
34 mg of FR-900523 were recrystallized from the same solvent as colorless needles. Condition I: Column; YMCA-302 (ODS, 6^x 150mm), mobile phase; MeOH -CH3CN -0.5% aq TFA (4:4:2), flow rate; 1 ml/minute, detection; UV at 210nm, sample A; FR-900520 (plates), sample B ; FR-900523 (needles).
Condition II: Column; YMCA-303 (ODS, 4.6^x250mm), mobile phase; CH3CN-THF -50him phosphate buffer (pH 2.0) (3 : 2 : 5), flow rate; 1 ml/minute, detection; UVat 210 nm, sample; crude powder. Fig. 9 . Both compoundssuppressed lymphocyte reaction in a dose dependent fashion. In four experiments, the IC50 values were 0.55 nM and 1.6 nM, respectively.
FR-900520 had a inhibitory activity at a lower concentration than FR-900523. In addition, the IC50 value of FK-506 under the conditions used was 0.23 nM. Suppression of In Vitro EL-4 Growth A representative inhibition curve for EL-4 growth is presented in Fig. 10 . FR-900520 and FR- NOV. 1988 900523 were non-toxic at concentrations less than 3,200 nM, at which the percent inhibition was 18.9 % and 3.5 %, respectively. Antimicrobial Activities FR-900520 and FR-900523 showed antifungal activity against Aspergillus fumigatus IFO 5840 as described in Table 2 . The MIC values were 0.03^g/ml and 0.3 ywg/ml, respectively.
They had no inhibitory effect on bacteria or yeast at 100^g/ml.
Effect of FR-900520 on Skin Allograft Survival in Rats As shown in Table 3 , FR-900520 was dose-dependently effective and clearly prolonged skin allo- were added directly throughout the assay. CsA, a fungal metabolite, is a potent immunosuppressant with low myelotoxicity. It is widely used clinically in organ transplantation.
Furthermore, CsA has a potential as a useful drug for autoimmune diseases due to its specific mode of action. However, its clinical use is limited by the occurrence of CsA-induced nephrotoxicity.
Wehave searched for safer, more efficient immunosuppressants and isolated two novel compounds from the fermentation broth of Streptomyces hygroscopicus subsp. yakushimaensis No. 7238. The major and minor components were designated as FR-900520 and FR-900523, respectively. Reversed-phase chromatography led to their separation. They displayed remarkably broad chromatograms in reversed-phase HPLC (Fig. 4) . Their chromatograms and Rf values on silica gel TLCsuggested that FR-900520 and FR-900523 were very similar to FK-506 produced by Streptomyces tsukubaensis No. 9993. On the basis of spectroscopic analyses, the structures of FR-900520 and FR-900523 were found to be new classes of 23-membered macrolide lactones related to FK-506. As shown in Fig. 1 , R in FR-900520 and FR-900523 are ethyl and methyl groups, respectively, instead of the allyl group in FK-506. Further structural information will be reported separately. FR-900520 and FR-900523 show a suppressive effect on mouse MLR,which has been thought to be a representative reaction of IL-2 dependent T cell growth, at low concentration. In multiple experiments, the IC50 values were 0.55 nMand 1.6 nM, respectively. FR-900520 suppressed at about three times lower concentration than FR-900523.
Their toxic concentrations against T cell proliferation such as EL-4 lymphomawere more than 3,200 nM. Unpublished observations have revealed that they also inhibit IL-2 production. These results indicate that the two compoundsare more specific and lower-toxic immunosuppressants with the same type of action as FK-506. Fig. 9 shows that FR-900520 and FR-900523 have rather lower potency than FK-506. Of these compounds FR-900523, in which R is a methyl group, has the lowest potency, but much higher than that of CsA. In our previous paper1}, we reported that the IC50 value of CsA was 27 nM. In addition, FR07545115), which can be prepared by catalytic reduction of the allyl group in FK-506 to a propyl group, suppressed mouse MLRin a similar or lower concentration range than that of FR-900520under the same experimental conditions. Furthermore, the same result was observed in rat MLR(data not shown). These results suggest that the carbon chains in R, especially the double bond (Fig. 1 ) may affect the immunosuppressive activity. Table 3 shows that 10 and 32 mg/kg of FR-900520 prolong skin allograft survival in rats to 104 and 157 days, respectively. These data indicate that grafts continue to survive after the termination of treatment. Inamura et alP reported that the effective dose of FK-506 on skin allograft survival was 0.32 mg/kg or more, and 3.2 mg/kg prolonged survival up to 43 days. Comparison of these results indicates that though FR-900520 has a lower immunosuppressive potency than FK-506, FR-900520 may achieve a longer survival time when administered intramuscularilly at the highest dose. Thus, FR-900520 and FR-900523 have effective immunosuppressive properties in vitro and in vivo. This leads us to an expectation that they will prove useful as immunosuppressants in clinical organ transplantation as well as FK-506.
